BioVascular raises $10.87M

With the help of lead investor BB Biotech Ventures, BioVascular rounded up $10.87 million in series C financing. The San Diego, CA-based company plans on using the money to complete clinical trials of its two compounds, Saratin and BVI-007. Saratin--which is currently in Phase I/II--is being developed to reduce the failure of vascular grafts due to intimal hyperplasia. BVI-007 reduces platelet production without affecting platelet function, and is being studied in a Phase Ib dose selection clinical trial.

- see BioVascular's release for more

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.